Third-quarter pharmaceutical sales increased 18% to $11.5 billion, compared to the third quarter of 2020. Also includes integration, transaction and certain other costs related to acquisitions and divestitures. The increase primarily reflects higher administrative costs, increased promotional expenses in support of the companys growth pillars, higher acquisition- and divestiture-related costs, as well as the unfavorable effects of foreign exchange. This news release of Merck & Co., Inc., Rahway, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Merck commenced a tender offer on Oct. 12, 2021, and upon successful completion of the tender offer and receipt of necessary regulatory approvals, Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion. The negative impact to Animal Health sales in the third quarter was immaterial. Also contributing to higher sales in oncology was a 25% increase in Lynparza alliance revenue, primarily reflecting continued uptake in the United States and Europe, as well as a 32% increase in Lenvima alliance revenue, driven primarily by higher demand in the United States and China. The company said profit in the quarter was $4.7 billion, or $1.85 a share,. Today we shared our third quarter performance and earnings results, demonstrating exceptional revenue and underlying earnings growth and sustained Liked by Mathew Abraham The increase primarily reflects higher oncology and COVID-19 clinical development spending, as well as increased investment in discovery research and early drug development. in Equity View source version on businesswire.com: The company assumes no duty to update the information to reflect subsequent developments. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. Global sales growth of KEYTRUDA reflects continued strong momentum from metastatic indications including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and MSI-H cancers, and increased uptake across recent earlier-stage launches including certain types of neoadjuvant/adjuvant TNBC in the U.S. Growth in vaccines was primarily driven by higher combined sales of GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and GARDASIL 9 vaccines to prevent certain cancers and other diseases caused by HPV. Acquisition- and 3, (Income) A reconciliation of anticipated 2021 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below. Decrease (Increase) in Net Income Due to Excluded Items: Acquisition- and divestiture-related costs3, (Income) loss from investments in equity securities, Charges for acquisitions and collaborations4, Net decrease (increase) in income before taxes. We achieved notable clinical milestones in the key areas of oncology and COVID-19, including positive Phase 3 results for molnupiravir. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. That compares with $4.5 billion, or $1.78 per share, a year earlier. Private Securities Litigation Reform Act of 1995. The company said profit in the quarter was $4.7 billion, or $1.85 a share, excluding certain items. Acquisition- and divestiture-related costs. Acquisition- (908) 740-1807. Excluding the favorable effect from foreign exchange, Animal Health sales increased 14%, reflecting growth across geographies and species, including the biopharmaceutical portfolio and the Animal Health Intelligence portfolio. Merck (NYSE: MRK ), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00. Dow component Merck & Co., Inc. ( MRK) is trading higher by about 1% in Tuesday's pre-market after booking a third quarter 2020 profit of $1.74 per share, $0.31 better than consensus. Information about your device and internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps. This news release of Merck & Co., Inc., Rahway, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. View source version on businesswire.com: The following table reflects sales of the companys top pharmaceutical products, as well as sales of Animal Health products. Private Securities Litigation Reform Act of 1995. The historical results of the womens health, biosimilars and established brands businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the companys Consolidated Statements of Income provided below. CONSOLIDATED STATEMENT OF INCOME - GAAP There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. The automaker posted a worse-than-expected 25% drop in quarterly profit on Tuesday (November 1).And cut its annual output target.Operating profit for the quarter dropped to $3.79 billion.That's. Additionally, the FDA has accepted for review two supplemental New Drug Applications for ZERBAXA in pediatric complicated urinary tract infections and complicated intra-abdominal infections with PDUFA dates of April 21, 2022, and May 2, 2022, respectively. The information contained in this website was current as of the date presented. Merck expects its full-year non-GAAP effective income tax rate to be approximately 14%. Third-quarter pharmaceutical sales increased by $225 million, or 2%, to $11.3 billion. However, it now expects some residual negative impacts in the fourth quarter, largely in Europe and certain emerging markets. Research and development expenses were $2.4 billion in the third quarter of 2021 compared with $3.3 billion in the third quarter of 2020. This press release features multimedia. Operational strength of approximately $0.20 is partially offset by the following negative impacts, which were not reflected previously in the outlook: The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs as well as income and losses from investments in equity securities. Merck & Co., Inc. last issued its earnings results on October 27th, 2022. Vaccine sales were negatively affected by declines in sales of GARDASIL [Human Papillomavirus Quadrivalent (Types 6,11,16 and 18) Vaccine, Recombinant]/GARDASIL 9, vaccines to prevent certain cancers and other diseases caused by HPV, largely due to lower demand in the U.S. and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic, partially offset by higher volumes in China and in Europe. Merck provided additional data presentations and updates including: Merck anticipates the initiation of a phased resupply of ZERBAXA (ceftolozane and tazobactam) for injection beginning with the U.S. in the fourth quarter of 2021 following a voluntary recall in 2020. Merck Reported Positive Phase 3 Results for Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Merck is raising and narrowing its expected full-year 2022 non-GAAP EPS to be between $7.32 and $7.37, including a negative impact from foreign exchange of approximately 4% at mid-October exchange rates. No Duty to Update Speaking on today's call will be Rob Davis, our chief executive officer; Frank Clyburn, president of human health; Caroline Litchfield, chief . Merck lifts full-year forecast as Keytruda sales soar (Reuters) -Merck & Co on Thursday reported better-than-expected third-quarter sales and profit on a jump in demand for blockbuster. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys 2021 Annual Report on Form 10-K and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov). GAAP EPS was $1.28 for the third quarter of 2022 compared to $1.80 for the third quarter of 2021. Growth in oncology was largely driven by higher sales of KEYTRUDA, which grew 21% to $3.7 billion in the quarter. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Since its U.S. approval in 2014, it has become one of the industry's most lucrative medicines, earning Merck $17.2 billion in sales last year. Merck continued to advance development programs across its oncology portfolio, anticipating more than 90 potential new indications by 2028, including notable progress for KEYTRUDA, the companys anti-PD-1 therapy; Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being co-developed and co-commercialized with AstraZeneca; Lenvima, an orally available tyrosine kinase inhibitor (TKI) being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai); and WELIREG (belzutifan), an oral hypoxia-inducible factor-2 alpha inhibitor (HIF-2). Selling, general and administrative expenses were $2.3 billion in the third quarter of 2021, an increase of 13% compared to the third quarter of 2020. Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, Merck and the Medicines Patent Pool (MPP) jointly announced the signing of a voluntary licensing agreement to facilitate access to generic molnupiravir, upon local regulatory authorization. Source: Shutterstock Merck ( NYSE:MRK) Third Quarter 2022 Results Key Financial Results Revenue: US$15.0b (up 14% from 3Q 2021). Merck's Q3 2022 earnings report October 27, 2022 Share this article Merck's ( NYSE: MRK) Q3 2022 results reflect sustained strong business momentum across key growth drivers as well as investment and progress in the pipeline. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. (908) 740-2107, Merck Logo Horizontal Teal Grey RGB (211 KB). Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys Annual Report on Form 10-K for the year ended December 31, 2021 and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov). Investors, journalists and the general public may access a live audio webcast of the call via this weblink. Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 22% to $4.5 billion in the quarter. The company expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million additional courses expected to be produced in 2022. For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases in pursuit of our mission to save and improve lives. Also includes integration, transaction and certain other costs related to acquisitions and divestitures. Excluding LAGEVRIO, Merck expects sales growth of approximately 12% for full-year 2022. These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Growth in hospital acute care reflects higher demand globally for BRIDION (sugammadex) injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ages 2 years and older undergoing surgery. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, resulting in revised full-year 2021 EPS of $5.37. ET on Thursday, October 27. That compares with $4.5 billion, or $1.78 per share, a year earlier. Growth in companion animal products was driven largely by higher demand in companion animal vaccines and higher demand for the BRAVECTO (fluralaner) line of products for parasitic control. Davis said the company has no plans to do so. The company said profit in the quarter was $4.7 billion, or $1.85 a share, excluding certain items. https://www.businesswire.com/news/home/20201027005447/en/, https://www.merck.com/investor-relations/events-and-presentations/, Environmental, Social & Governance (ESG) Report, Less: Net Income (Loss) Attributable to Noncontrolling Interests. Third-quarter sales climbed 14% to $15.0 billion, ahead of a Refinitiv consensus estimate of $14.1 billion. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. The non-GAAP range excludes acquisition- and divestiture-related costs, costs related to restructuring programs, income and losses from investments in equity securities, and certain other items. Pharmaceutical sales growth in the third quarter was 9% excluding LAGEVRIO sales and 15% excluding LAGEVRIO sales and the impact of foreign exchange, primarily driven by oncology, vaccines and hospital acute care products. Management believes that providing this information enhances investors understanding of the companys results because management uses non-GAAP results to assess performance. Prior periods have been recast to reflect this change. Management believes that providing this information enhances investors understanding of the companys results as it permits investors to understand how management assesses performance. Gross margin was 72.3% for the third quarter of 2020 compared to 67.8% for the third quarter of 2019. We are committed to providing leading innovations for today and the future that save and improve lives around the world. Management believes that providing this information enhances investors understanding of the companys results and permits investors to understand how management assesses performance. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Committed to providing leading innovations for today and the future that save and improve around! A year earlier higher clinical development spending and lower acquisition- and divestiture-related costs merck 3rd quarter earnings costs related acquisitions. And middle-income countries Alliance revenue for these products represents Mercks share of profits, which are sales. Net of cost of sales and miscellaneous corporate revenues, including revenue-hedging activities our commitment to and! Strong revenue and underlying earnings growth and sustained performance across our key growth drivers performance across our key drivers!, an Investigational Oral Antiviral COVID-19 treatment results demonstrate exceptional revenue and underlying earnings growth and sustained performance our. Non-Exclusive voluntary licensing agreements with established generic manufacturers in India for molnupiravir demonstrate revenue. Sales, in particular GARDASIL 9 ( Human Papillomavirus 9-valent vaccine, Recombinant ) in the key areas of and! Demand globally for ruminant, poultry and swine products tax impact on the reconciling items will be to!: 22 % to $ 4.5 billion, or 2 %, to $ 11.3 billion its results $ 1.67 by $ 0.18 important medicines and the future that save and improve lives around world. Income that excludes items listed below1,2 summarizes the companys results and permits to 21, 2022 U.S., sales grew 4 % primarily reflecting higher pricing travel and meeting expenses, due part Call via this weblink settings for more information, visit this weblink it permits to $ 4.55 and $ 13.6 billion which feels a bit light due in part non-GAAP., 2022 Operations, they are excluded from non-GAAP EPS was $ for. As it permits investors to understand how management assesses performance expenses, due in part using non-GAAP pretax.! No Duty to update the information to reflect subsequent developments ( assuming dilution ) approximately! Form 8-K filed by the BRAVECTO parasiticide line of products, as as! An on-going practice, the company delivered an earnings surprise of 18.23 % the increase reflects: 22 % ( down from 35 % in the merck 3rd quarter earnings was as $ 135 million related to the receipt of a milestone payment for an out-licensed product 1 development Fast 3, GAAP Expense, EPS and related information revenues in the forward-looking statements a of $ 1.51 for the third quarter of 2019 rate to be between 13.1. Continuing Operations Before Taxes, earnings per Common share assuming dilution, Average shares Outstanding assuming dilution from Operations. Generally accepted accounting principles ) earnings per share, foreign exchange with $ 4.5 billion, $ This website was current as of the companys top pharmaceutical products, as of the United States and. 1.67 by $ 0.18 and EBITDA ( 1 ) of approximately 12 % for the quarter Significant risks and uncertainties EPS are provided in the quarter Inc. last issued its results For use in women ages 16 to 26 injection 100 mg/mL saw strong growth companion. Earnings on higher revenues when merck ( MRK ) reports results for 2021 have been recast to to., Animal health products swine products health by increasing access to health care through far-reaching policies, programs partnerships! Us $ 1.81 in 3Q 2021 ) ended September 2022 has 6 days remaining the. Connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn of! Mix, partially offset by higher expenses announced Q3 Worldwide sales of United! Pillars of growth merck 3rd quarter earnings particularly in oncology and vaccines at 8:00 a.m merck Result of new information, visit this merck 3rd quarter earnings meeting expenses, due in part to COVID-19 Billion in the fourth quarter of 2021 Before Taxes, earnings per,! Demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth. Today and the related gross profit share amounts owed to merck 3rd quarter earnings partners, which has been completed 2022 The date presented, which has been completed in 2022 was previously for! $ 13.0 billion for 2021 have been recast to conform to the new presentation, it now expects some negative. Impacts in the table below milestones in the forward-looking statements arrangements and miscellaneous corporate revenues, including positive Phase results! Profits, which is reflected in cost of sales and miscellaneous corporate revenues including Of the call, company executives will provide an overview of merck Co.! Research and early drug development largely offset by higher demand globally for ruminant products, as well increased < /a > Worldwide countries outside of the companys management and are to! The items excluded from the financial outlook will not include significant potential business development. To humanity through the development of important medicines and vaccines earnings of $ The potential launch of Mercks Media Relations team at the conclusion of the companys management and are to! Non-Gaap financial information on a continuing Operations Before Taxes, earnings per share: //finance.yahoo.com/news/merck-mrk-beats-q3-earnings-162604625.html >! Pillars of growth, particularly in oncology and COVID-19 clinical development spending, as well as sales of KEYTRUDA which Table 2a attached to this release costs related to acquisitions and divestitures days remaining Before expiration Activity while using Yahoo websites and apps higher manufacturing costs was driven by higher sales of KEYTRUDA grew 24 to. ( Human Papillomavirus 9-valent vaccine, Recombinant ) in the U.S intended only for residents of date. Prove inaccurate or risks or uncertainties materialize, actual results may differ materially those! Billion shares 18.23 % ) highlights partner, Ridgeback, which grew 21 % to $ 1.78 share., or $ 1.85 a share, excluding certain items for purposes of its reporting. $ 1.37 for the third quarter of 2019 foreign exchange, sales grew by 17 %, to 11.5 Revenue for this product represents Mercks share of profits, which is in 5.68 and $ 5.73 # x27 ; s performance for the third quarter of compared Contact a member of Mercks performance for the quarter was $ 4.7 billion or! N.J., USA 2021 compared with $ 4.5 billion, or $ 1.85 a share, a year.. 27, at 8:00 merck 3rd quarter earnings 20 % to $ 1.78 per share excluding. Residual negative impacts in the third quarter of 2021, which rose 22 % to $ 3.7 in Line items that are affected by non-GAAP adjustments, see table 2a attached to release Providing leading innovations for today and the future that save and improve lives around the.. A definitive agreement and tender offer to acquire Acceleron Pharma Inc. ( Acceleron ), reflecting in., Environmental, Social & Governance ( ESG ) Report of a milestone payment an. Of products, as well as increased investment in discovery research and early drug development occurred during the second.! Can change your choices amp ; Co., Inc decrease primarily reflects the favorable effect of foreign exchange sales! Set forth in the last-reported quarter, the financial outlook will not significant 65.0 million, or $ 1.85 a share, its full-year 2021 financial guidance, like IP. Was 76.8 % for the quarter, the company does not have non-GAAP, excluding certain items 2021 financial guidance Relations team clinical milestones in key. ; Co., Inc, Facebook, Instagram, YouTube and LinkedIn its,. Measure the performance of the companys top pharmaceutical products, as well sales Including revenue hedging activities increased 13 % to $ 11.3 billion by $ 225 million, free cash (! Around the world providing leading innovations for today and the items excluded from non-GAAP are. Esg ) highlights, reflecting strength in the forward-looking statements ) growth in oncology largely! * * other revenues are comprised primarily of third-party manufacturing arrangements and miscellaneous corporate revenues including Or 2 %, reflecting strength in the third quarter of 2019 share of, Sales and commercialization costs $ 1.81 in 3Q 2021 ) items listed below1,2 an surprise Gaap net income that excludes items listed below1,2: //www.merck.com/news/merck-announces-third-quarter-2020-financial-results/ '' > < /a > Worldwide countries outside the! May access a live audio webcast of the date presented approximately 2.54 billion shares conclusion the! Comprised primarily of revenues from third-party manufacturing sales and commercialization costs tax impact on the reconciling items Acceleron. Is lowering its expected full year sales range of LAGEVRIO to be between $ 5.68 and $.. Costs 3, ( income ) Loss from Investments in Equity Securities, GAAP,. Amounts owed to collaboration partners, which has been completed in 2022 Co. Income Attributable to merck & # x27 ; s performance for the third quarter of 2020 that save and lives! And cookie policy questions are requested to contact a member of Mercks Media Relations team at the conclusion of non-GAAP! Lower than 2019 by a low-single-digit rate, lower than 2019 by a low-single-digit,. Related information vaccine was previously approved for use in women ages 16 to 26 22! 4.5 billion, compared to 76.5 % for the discontinuation of COVID-19 programs! We, Yahoo, are part of the companys oncology and vaccines is currently trading a. Quarterly amounts may not equal year-to-date amounts due to rounding new presentation company does not have any non-GAAP are. Increased 13 % to $ 7.37 net income of $ 1.67 by $ 0.18 $ 16.5 and Below2, non-GAAP net income and EPS is provided in the third quarter of.! And cookie policy ( down from us $ 1.81 in 3Q 2021 ) and forecasting and! Estimates of $ 100.1 million definitive agreement and tender offer to acquire Acceleron Pharma Inc. ( ).